Liver disease bleeding management: which treatment is used when there is active bleeding or before surgery?

Liver disease bleeding management: which treatment is used when there is active bleeding or before surgery?

• A. Desmopressin
• B. Vitamin K
• C. Fresh frozen plasma
• D. Cryoprecipitate

Answer: (C)

When the liver is damaged, it can’t make enough clotting factors, so bleeding risk rises across multiple pathways. In this situation, you need something that can rapidly supply a wide range of coagulation factors to stop bleeding or to safely proceed with surgery. Fresh frozen plasma fits that need because it contains most of the coagulation factors (II, VII, IX, X, and others) in a ready-to-use plasma form, helping to quickly correct abnormal clotting tests and restore hemostasis. Vitamin K only helps if there’s a true deficiency or warfarin effect and requires functioning liver to produce factors; in liver disease with impaired synthesis, it often doesn’t correct the coagulopathy promptly. Desmopressin can improve certain platelet function or specific factor VIII release but doesn’t address the broad deficiency of clotting factors seen in liver failure, so it’s not the primary replacement shown to correct active bleeding or preoperative coagulopathy. Cryoprecipitate supplies fibrinogen and some other factors but isn’t the broad-spectrum fix that liver disease–related coagulopathy requires. Fresh frozen plasma remains the best choice for rapid, broad factor replacement in this scenario.

When the liver is damaged, it can’t make enough clotting factors, so bleeding risk rises across multiple pathways. In this situation, you need something that can rapidly supply a wide range of coagulation factors to stop bleeding or to safely proceed with surgery. Fresh frozen plasma fits that need because it contains most of the coagulation factors (II, VII, IX, X, and others) in a ready-to-use plasma form, helping to quickly correct abnormal clotting tests and restore hemostasis.

Vitamin K only helps if there’s a true deficiency or warfarin effect and requires functioning liver to produce factors; in liver disease with impaired synthesis, it often doesn’t correct the coagulopathy promptly. Desmopressin can improve certain platelet function or specific factor VIII release but doesn’t address the broad deficiency of clotting factors seen in liver failure, so it’s not the primary replacement shown to correct active bleeding or preoperative coagulopathy. Cryoprecipitate supplies fibrinogen and some other factors but isn’t the broad-spectrum fix that liver disease–related coagulopathy requires. Fresh frozen plasma remains the best choice for rapid, broad factor replacement in this scenario.